Assyro AI

FDA Orange Book · active-ingredient family

Iron sucrose

Iron sucrose is approved as 1 brand and 3 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:VENOFER · NDA 021135

1

Brand (NDA)

3

Generics (ANDA)

0

Listed patents

3

Exclusivity periods

Brand (NDA) products · injectable

ProductApplicantApplicationTEApproved
VENOFERRLD×5AM REGENTNDA 021135ABMar 20, 2005

Generic (ANDA) products (3)

ProductApplicantApplicationTEApproved
IRON SUCROSE×3INTL MEDICATION SYSANDA 208977ABAug 08, 2025
IRON SUCROSE×3MYLAN LABS LTDANDA 212559ABAug 08, 2025
IRON SUCROSE×3SANDOZANDA 212340ABAug 08, 2025

Marketing exclusivity (3)

  • CGTFDA marketing exclusivity

    Feb 08, 2026

    4 mo ago

  • CGTFDA marketing exclusivity

    Feb 07, 2026

    4 mo ago

  • CGTFDA marketing exclusivity

    Feb 07, 2026

    4 mo ago

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Iron sucrose — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.